Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone303-625-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$95.39 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions
What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
How were Clovis Oncology's earnings last quarter?
Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings results on Tuesday, February, 26th. The biopharmaceutical company reported ($1.88) EPS for the quarter, missing the consensus estimate of ($1.72) by $0.16. The biopharmaceutical company had revenue of $30.40 million for the quarter, compared to analyst estimates of $30.46 million. Clovis Oncology had a negative net margin of 385.80% and a negative return on equity of 147.39%. The business's revenue for the quarter was up 78.4% on a year-over-year basis. During the same period last year, the company posted ($1.04) earnings per share. View Clovis Oncology's Earnings History.
When is Clovis Oncology's next earnings date?
What price target have analysts set for CLVS?
12 brokers have issued 1 year price targets for Clovis Oncology's shares. Their predictions range from $23.00 to $86.00. On average, they expect Clovis Oncology's stock price to reach $45.5022 in the next twelve months. This suggests a possible upside of 74.1% from the stock's current price. View Analyst Price Targets for Clovis Oncology.
What is the consensus analysts' recommendation for Clovis Oncology?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clovis Oncology.
What are Wall Street analysts saying about Clovis Oncology stock?
Here are some recent quotes from research analysts about Clovis Oncology stock:
- 1. According to Zacks Investment Research, "Clovis reported dismal fourth-quarter results wherein its earnings and sales missed estimates. Sales of the company’s sole marketed drug Rubraca recovered in the fourth quarter of 2018 on the back of awareness programs. Approval in second-line maintenance setting for ovarian cancer irrespective of BRCA-mutation is encouraging. Successful development of Rubraca in several ongoing studies targeting different types of ovarian cancer patients is likely to bolster the prospect of the drug. The company is actively working on expanding the label of Rubraca as monotherapy or combination therapy in and beyond ovarian cancer. However, Rubraca faces strong competition from other PARP inhibitors in the market, Lynparza and Zejula. Moreover, competition is likely to increase with several PARP inhibitors under development. Clovis’ shares have underperformed the industry in the past six months." (3/6/2019)
- 2. JPMorgan Chase & Co. analysts commented, "Clovis’ 4Q report was as expected following the top-line pre-announcement at The J.P. Morgan Healthcare Conference. Importantly, all key Rubraca clinical trials remain on track with the next material data updates likely at ESMO in September. In the meantime, we expect investors to continue to focus on the strategic value of the company, particularly in the wake of the GSK/TSRO deal. We are also increasingly asked about CLVS’s cash outlook given an accelerating operating spend and a first round of converts due in 2021 (~$284M). While these questions are likely to persist, we anticipate they will be secondary to the company’s strategic potential." (2/27/2019)
Has Clovis Oncology been receiving favorable news coverage?
News headlines about CLVS stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Clovis Oncology earned a news sentiment score of -3.6 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
Are investors shorting Clovis Oncology?
Clovis Oncology saw a decrease in short interest in February. As of February 28th, there was short interest totalling 10,702,247 shares, a decrease of 10.3% from the February 15th total of 11,933,280 shares. Based on an average daily volume of 2,454,799 shares, the short-interest ratio is currently 4.4 days. Currently, 21.5% of the company's shares are sold short. View Clovis Oncology's Current Options Chain.
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include Array Biopharma (ARRY), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), FibroGen (FGEN), Horizon Pharma (HZNP), Amneal Pharmaceuticals (AMRX), Taro Pharmaceutical Industries (TARO), TESARO (TSRO), HUTCHISON CHINA/S (HCM), Agios Pharmaceuticals (AGIO), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC) and Evotec (EVTCY).
What other stocks do shareholders of Clovis Oncology own?
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the folowing people:
- Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
- Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
- Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
- Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
- Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)
Who are Clovis Oncology's major shareholders?
Clovis Oncology's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (5.22%), Samlyn Capital LLC (1.91%), Geode Capital Management LLC (1.09%), Geode Capital Management LLC (1.09%), Norges Bank (0.88%) and Elk Creek Partners LLC (0.72%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.
Which major investors are selling Clovis Oncology stock?
CLVS stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Amundi Pioneer Asset Management Inc., Hudson Bay Capital Management LP, Bank of Montreal Can, MetLife Investment Advisors LLC, Principal Financial Group Inc., Stifel Financial Corp and California Public Employees Retirement System. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, James C Blair, Lindsey Rolfe and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.
Which major investors are buying Clovis Oncology stock?
CLVS stock was purchased by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, Orbimed Advisors LLC, Norges Bank, Elk Creek Partners LLC, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Sofinnova Investments Inc. and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Clovis Oncology.
How do I buy shares of Clovis Oncology?
Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clovis Oncology's stock price today?
One share of CLVS stock can currently be purchased for approximately $26.13.
How big of a company is Clovis Oncology?
Clovis Oncology has a market capitalization of $1.38 billion and generates $95.39 million in revenue each year. The biopharmaceutical company earns $-368,010,000.00 in net income (profit) each year or ($7.07) on an earnings per share basis.
What is Clovis Oncology's official website?
How can I contact Clovis Oncology?
Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]
MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
